| Target Molecule | Octreotide |
| Synonyms | Sandostatin, SMS 201-995, Longastatin, Octreotide Acetate |
| CAS Number | 83150-76-9 (free base); 79517-01-4 (acetate salt) |
| Sequence (3-Letter) | H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol (cyclic Cys2–Cys7 disulfide) |
| Sequence (1-Letter) | fCFwKTC-Thr-ol |
| Molecular Formula | C₄₉H₆₆N₁₀O₁₀S₂ (free base) |
| Molecular Weight | 1019.24 (free base) |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥98%, ≥99% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate (standard pharmaceutical salt), TFA, or custom salt options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) with C-Terminal Threoninol Assembly |
| Modification Options | C-terminal threoninol incorporation, intramolecular disulfide bridging, D-amino acid substitution, stable isotope labeling (13C, 15N), linear precursor standards |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and disulfide connectivity verification provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Octreotide (CAS 83150-76-9) is a synthetic cyclic octapeptide somatostatin analogue featuring D-phenylalanine, D-tryptophan, an intramolecular Cys2–Cys7 disulfide bridge, and a C-terminal threoninol amino alcohol group (H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol). We target this sequence to supply high-purity reference materials and raw materials for acromegaly and neuroendocrine tumor research.
Incorporating a C-terminal threoninol (alcohol terminus) requires specialized pre-loaded resins and custom cleavage protocols rather than standard acidolytic release. Our peptide synthesis platform combines optimized Solid-Phase Peptide Synthesis (SPPS) with directed oxidative folding between Cys2 and Cys7, ensuring precise ring closure and high structural integrity.
Yes. We provide specialized peptide modification services for somatostatin analogues. Options include the synthesis of uncyclized linear precursors as critical impurity reference standards, site-specific stable isotope labeling (13C, 15N) for quantitative mass spectrometry (LC-MS/MS), and D-Trp diastereomer controls.
Our manufacturing infrastructure scales production from milligram-level analytical batches to multigram and kilogram commercial quantities. We optimize preparative HPLC purification and controlled counter-ion exchange (ensuring acetate salt conversion) to guarantee strict batch-to-batch consistency.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, disulfide verification, impurity profiling, analytical method validation, and regulatory documentation to support complex drug development pipelines.
Octreotide (CAS 83150-76-9), commercially known as Sandostatin, is a synthetic cyclic octapeptide acting as a potent somatostatin receptor agonist. Defined by the sequence H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol with a Cys2–Cys7 disulfide bridge and a C-terminal threoninol residue, it exhibits greatly enhanced metabolic stability and a prolonged half-life compared to native somatostatin. Synpeptide delivers comprehensive custom synthesis solutions for this target molecule, showcasing our technical expertise in C-terminal amino alcohol incorporation, chiral control, and CDMO manufacturing.
Constructing Octreotide requires specialized chemical methodologies due to the presence of D-amino acids and the unique C-terminal alcohol functionality. Standard SPPS yields carboxylic acids or amides, necessitating pre-loaded threoninol resins and tailored cleavage protocols. Our custom peptide synthesis platform resolves these hurdles using optimized Solid-Phase Peptide Synthesis (SPPS) protocols followed by directed oxidative folding under high-dilution conditions. By regulating reaction kinetics, we suppress polymeric aggregates and deliver raw materials with rigorous purity specifications (typically ≥98% or ≥99% via HPLC).
Because structural integrity depends heavily on correct disulfide pairing and stereochemical purity, robust analytical validation is essential. Incomplete oxidation yields linear precursors, while chiral inversion produces diastereomeric impurities. Through our peptide modification services, we synthesize uncyclized linear precursors and D-Trp diastereomers as essential reference standards for stability-indicating assays. We also incorporate stable isotopes (13C, 15N) for pharmacokinetic bioanalysis.
Transitioning a modified cyclic octapeptide from analytical scale to commercial volume demands robust downstream process engineering. We execute large-scale peptide synthesis for Octreotide utilizing continuous-flow oxidation systems and high-capacity preparative HPLC purification. Our facilities accommodate requirements from milligram research batches to kilogram commercial lots, ensuring uniform counter-ion exchange (consistently achieving the pharmaceutical acetate salt form) across all production volumes.
We deliver comprehensive technical support as a fully integrated peptide CDMO. Our development specialists assist pharmaceutical partners with process optimization, stability testing, impurity identification, and analytical method validation. Every batch is released with complete analytical documentation—including COA, HPLC purity traces, and exact mass confirmation—ensuring regulatory alignment for downstream therapeutic programs.
